FR2901478B1 - MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE - Google Patents

MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE

Info

Publication number
FR2901478B1
FR2901478B1 FR0604685A FR0604685A FR2901478B1 FR 2901478 B1 FR2901478 B1 FR 2901478B1 FR 0604685 A FR0604685 A FR 0604685A FR 0604685 A FR0604685 A FR 0604685A FR 2901478 B1 FR2901478 B1 FR 2901478B1
Authority
FR
France
Prior art keywords
multimicroparticulated
oral pharmaceutical
pharmaceutical form
prolonged release
prolonged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0604685A
Other languages
French (fr)
Other versions
FR2901478A1 (en
Inventor
Florence Guimberteau
Frederic Dargelas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Ireland Ltd
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Priority to FR0604685A priority Critical patent/FR2901478B1/en
Priority to JP2009511528A priority patent/JP5654750B2/en
Priority to EP07729498A priority patent/EP2040685A2/en
Priority to CA2651451A priority patent/CA2651451C/en
Priority to CNA200780018905XA priority patent/CN101453994A/en
Priority to PCT/EP2007/055069 priority patent/WO2007135193A2/en
Publication of FR2901478A1 publication Critical patent/FR2901478A1/en
Application granted granted Critical
Publication of FR2901478B1 publication Critical patent/FR2901478B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
FR0604685A 2006-05-24 2006-05-24 MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE Active FR2901478B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0604685A FR2901478B1 (en) 2006-05-24 2006-05-24 MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE
JP2009511528A JP5654750B2 (en) 2006-05-24 2007-05-24 Sustained release multiparticulate oral pharmaceutical form
EP07729498A EP2040685A2 (en) 2006-05-24 2007-05-24 Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
CA2651451A CA2651451C (en) 2006-05-24 2007-05-24 Extended release oral multimicroparticle dosage form
CNA200780018905XA CN101453994A (en) 2006-05-24 2007-05-24 Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
PCT/EP2007/055069 WO2007135193A2 (en) 2006-05-24 2007-05-24 Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604685A FR2901478B1 (en) 2006-05-24 2006-05-24 MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE

Publications (2)

Publication Number Publication Date
FR2901478A1 FR2901478A1 (en) 2007-11-30
FR2901478B1 true FR2901478B1 (en) 2015-06-05

Family

ID=37435577

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0604685A Active FR2901478B1 (en) 2006-05-24 2006-05-24 MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE

Country Status (6)

Country Link
EP (1) EP2040685A2 (en)
JP (1) JP5654750B2 (en)
CN (1) CN101453994A (en)
CA (1) CA2651451C (en)
FR (1) FR2901478B1 (en)
WO (1) WO2007135193A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
ES2360102T3 (en) 2003-03-26 2011-05-31 Egalet A/S SYSTEM FOR CONTROLLED RELEASE OF MORPHINE.
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
JP2011506318A (en) 2007-12-06 2011-03-03 デュレクト コーポレーション Oral pharmaceutical formulation
NZ592276A (en) * 2008-09-18 2012-12-21 Purdue Pharma Lp PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
JP6141583B2 (en) * 2010-02-24 2017-06-07 シマ ラブス インク． Abuse-resistant formulation
EP3272342B1 (en) * 2011-03-23 2021-05-26 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
CN102516473B (en) * 2011-12-14 2013-07-24 华南理工大学 Copolymerized nano composite hydrogel for intelligent separation of cell sheets as well as preparation method and application thereof
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936746C (en) * 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
MX2018016411A (en) 2016-06-29 2019-05-09 Cannscience Innovations Inc Decarboxylated cannabis resins, uses thereof and methods of making same.
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
CN111841508B (en) * 2020-07-28 2021-08-17 南昌航空大学 Sulfosalicylic acid modified chitosan/silicon dioxide microspheres and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JP3677156B2 (en) * 1997-09-05 2005-07-27 武田薬品工業株式会社 Medicine
JP2002003366A (en) * 2000-06-23 2002-01-09 Freunt Ind Co Ltd Aqueous coating composition for solid medicine
BR0212020A (en) * 2001-08-06 2005-08-16 Euro Celtique Sa Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
ATE432065T1 (en) * 2002-03-26 2009-06-15 Euro Celtique Sa YELLOW COATED SUSTAINED RELEASE COMPOSITIONS
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
DE10250084A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
AU2004258894B2 (en) * 2003-07-17 2010-06-03 Patheon Softgels Inc. Controlled release preparations
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
CA2572352A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
ES2531735T3 (en) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical preparations with lower potential for abuse
FR2892937B1 (en) * 2005-11-10 2013-04-05 Flamel Tech Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING

Also Published As

Publication number Publication date
WO2007135193A2 (en) 2007-11-29
FR2901478A1 (en) 2007-11-30
EP2040685A2 (en) 2009-04-01
JP5654750B2 (en) 2015-01-14
WO2007135193A3 (en) 2008-06-26
CN101453994A (en) 2009-06-10
JP2009537610A (en) 2009-10-29
CA2651451C (en) 2013-08-20
CA2651451A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
FR2901478B1 (en) MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE
FR2881652B1 (en) MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
FR2892937B1 (en) MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
FR2951378B1 (en) ANTI-MEASURING SOLID ORAL PHARMACEUTICAL FORM WITH A SPECIFIC MODIFIED RELEASE PROFILE
DK2077729T3 (en) ORAL PROBIOTIC DOSAGE FORMS
DK2073795T3 (en) Abuse-safe drug formulation
DK2041139T3 (en) Pharmaceutical compounds
DK1924151T3 (en) Controlled release oral release system
BRPI0808889A2 (en) ORAL DISINTERRANTING PILL
BRPI0715712A2 (en) PHARMACEUTICAL COMPOSITION
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
BRPI0719393A2 (en) Pharmaceutical Composition
BRPI0719394A2 (en) Solid medicinal preparation
FR2959935B1 (en) ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM
BRPI0818852A2 (en) Oral antiemetic contraceptive combination
ATE493119T1 (en) PHARMACEUTICAL COMPOSITION
BRPI0716445A2 (en) pharmaceutical composition
FR2934156B1 (en) ORAL ADMINISTRATION MEDICAMENT IN SOLID FORM
BRPI0720234A2 (en) PHARMACEUTICAL COMPOSITION
ATE534374T1 (en) ORAL PREPARATION WITH PIOGLITAZONE
DE602007007014D1 (en) printing device
FR2930147B1 (en) SOLID ORAL FORM WITH A DOUBLE RELEASE PROFILE
DE502007000038D1 (en) flexographic printing
DK2918286T3 (en) A PHARMACEUTICAL FORMULATION
BRPI0806938A2 (en) PHARMACEUTICAL COMPOSITION CONTAINING A CAMPTOTECIN DERIVATIVE

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

TP Transmission of property

Owner name: FLAMEL IRELAND LIMITED, IE

Effective date: 20151119

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12